Treatment Patterns, Complications, and Disease Relapse in a Real-world Population of Patients with Moderate-to-severe Ulcerative Colitis Initiating Immunomodulator Therapy
Edward V. Loftus(Mayo Clinic), Allison Luo(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 10
Related Papers
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based Cohort
|Gastroenterology|2010|781
Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a united states community
|Gastroenterology|2003|452
Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Azathioprine and 6-Mercaptopurine: A Meta-analysis
|Clinical Gastroenterology and Hepatology|2014|405